Form 4: Travere Therapeutics Executive Exercises Options and Sells Shares
SEC Form 4 Filing
A Travere Therapeutics executive, Sandra Calvin, exercised stock options and sold shares on December 26, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Sandra Calvin, SVP and Chief Accounting Officer at Travere Therapeutics, exercised 15,000 stock options at a price of $12.67 per share on December 26, 2024.
- Following the exercise of options, Ms. Calvin sold 15,000 shares of common stock at a weighted average price of $17.2185 per share.
- The sales were executed under a pre-arranged trading plan adopted on September 9, 2024, to comply with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
- After these transactions, Ms. Calvin beneficially owns 54,927 shares of Travere Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction by an executive, with no indication of positive or negative sentiment. It is a standard SEC filing.
Industry Context
This is a routine filing related to insider trading activity. It is common for executives to exercise stock options and sell shares, often under pre-arranged trading plans to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among publicly traded companies to allow insiders to sell shares without violating insider trading laws.
- The reported transactions are typical for executives who receive stock options as part of their compensation package.
- The price range of the share sales is within the normal fluctuations of the stock price.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are routine and do not indicate any change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 09/09/2024 | Date the 10b5-1 trading plan was adopted by the reporting person. |
| 12/26/2024 | Date of the stock option exercise and share sale. |
| 12/27/2024 | Date the SEC Form 4 was signed. |
| 01/02/2025 | Expiration date of the employee stock option. |
Keywords
Travere Therapeutics, stock options, insider trading, SEC Form 4, Rule 10b5-1, share sale, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.